Rapid Micro Biosystems (RPID) TD Cowen 46th Annual Health Care Conference summary

Business Overview and Market Context

• Focuses on automating microbial quality control in pharmaceutical manufacturing, a process critical for regulatory compliance and historically lacking innovation.

• Developed the Growth Direct platform, a fully automated, high-throughput system that replaces manual, error-prone processes with digital, AI-driven solutions.

• Serves a global customer base, including 75% of the top 20 pharma companies and 86% of approved CAR-T manufacturers, with strong penetration in biologics and cell and gene therapy manufacturing.

• Recurring revenue is a key business driver, with 190 system placements worldwide and 155 validated for GMP environments.

Financial Performance and Growth Strategy

• Achieved $33.6M in 2025 revenue, representing 20% year-over-year growth, with $17.8M in recurring revenue and 190 cumulative system placements.

• Exceeded 2025 revenue guidance, marking 13 consecutive quarters of meeting or exceeding targets, and reported record quarterly revenue in Q4 2025.

• Gross margin improved significantly, supported by a strengthened balance sheet and a $45M term loan facility.

• 25% CAGR over several years, with recurring consumables and service revenue driving growth.

• Land-and-expand strategy enables deeper penetration within existing customers and expansion into new geographies and modalities.

Strategic Partnerships and Innovation

• Strategic partnership with MilliporeSigma includes a five-year, co-exclusive global distribution and collaboration agreement with minimum purchase commitments, preferred procurement rates, and joint innovation initiatives.

• Partnership expected to accelerate growth, improve gross margins, and drive innovation, with a meaningful impact anticipated in 2026 and beyond.

• R&D focuses on automating legacy workflows and leveraging data to provide actionable insights for customers.